COVID-19 Vaccine and Bladder Cancer: Friend or Foe?

This is a letter to the editor on the discussion on COVID-19 vaccine and bladder cancer

Evaluación de la capacidad antioxidante y el índice glicémico de frutos promisorios amazónicos del Perú

Determinar la capacidad antioxidante y el Índice glicémico de frutos promisorios amazónicos del Perú. La Capacidad antioxidante de los jugos de frutos amazónicos diluidos al 1/100, se determinó mediante el método DPPH expresado como el porcentaje de inhibición, tomando como referencia el jugo de Limón diluido al 1/100. El índice glicémico expresado en porcentaje fue determinado por el área bajo la curva del alimento en prueba y de la glucosa, considerando el área de la curva de glucosa como el 100 % Se utilizaron 12 ratas albinas machos con peso aproximado de 250 g, a los cuales se determinó la glicemia (en ayunas) basal (tiempo cero) posteriormente se administró glucosa (estándar) por vía orogástrica a la dosis de 50 mg/70 g de peso, determinando la glicemia a diferentes tiempos (15, 30, 45, 60, 90, 120, 150 min). Días posteriores se administró el alimento de prueba por vía orogástrica a la dosis equivalente a la de la glucosa dependiendo del contenido de carbohidratos del alimento, determinando la glicemia a los diferentes tiempos. La capacidad antioxidante expresado como porcentaje de inhibición fueron: cajú 76%, cajá 201%, arazá 268%, caimito 302%, mango ciruela 353% y pitujaya 524% y los IG fueron: cajú 75,8 %, cajá 74%, caimito 71,6 %, mango ciruela 59,7%, pitujaya 51,8% y arazá 43,8%. Los frutos estudiados tienen alta capacida

Nuevos datos de actividad tectónica durante el Pleistoceno Superior-Holoceno en el sector oriental de la plataforma continental del Golfo de Cádiz (SO de Iberia)

La realización de dos campañas de adquisición de datos geofísicos del suelo y subsuelo marino en el año 2010, mediante la utilización de técnicas acústicas de muy alta resolución, ha permitido ampliar el conocimiento de dos sectores de la plataforma continental española en el Golfo de Cádiz, comprendidos entre la desembocadura del río Guadalquivir y la Bahía de Cádiz, y entre Cádiz y Chiclana de la Frontera, respectivamente. En el primero se han localizado varias zonas de fracturas que se caracterizan en los perfiles de sísmica de muy alta resolución por fallas normales de alto ángulo y pequeño salto que desplaza claramente las unidades sedimentarias de edad Holoceno, se trata por tanto de fallas que se pueden considerar activas, si bien deben ser el reflejo en superficie de fallas profundas de mayor entidad. Mientras que en el segundo se ha analizado la morfología asociada a la actividad emergente de una estructura diapirica principal.Two oceanographic surveys have been carried out using very high resolution acoustic techniques in 2010. These surveys have allowed us to improve the knowledge of two sectors of the Spanish continental shelf in the Gulf of Cadiz: the first one, from the mouth of the Guadalquivir River to the Bay of Cadiz, and the second one, between Cadiz and Chiclana de la Frontera. In the first sector, we have located several fracture zones which are characterized in the seismic profiles as high angle normal faults of small vertical displacement. These faults displace clearly the Holocene sedimentary units. Therefore, these faults could be considered currently actives, although should be the surface expression of deeper and more significance faults. In the second sector, we have analyzed the associated morphology with the emerging activity of a main diapi

Vulnerable marine ecosystems and biological features of Gazul mud volcano (Gulf of Cádiz): A contribution towards a potential "Gulf of Cádiz" EBSA

The Gulf of Cádiz (GoC) represents an area of socioeconomic and scientific importance for oceanographic, geological and biological processes. An interesting feature of the GoC is the presence of a large amount of mud volcanoes (MVs) and diapirs that display different seepage, seabed types, oceanographic settings and biological communities. Detailed exploration of some MVs is still needed for detecting Vulnerable Marine ecosystems (VMEs) that seem to be rare in other areas of the GoC, improving the current knowledge on its biodiversity and ecological attributes. During different expeditions (MEDWAVES-ATLAS, INDEMARES-CHICA 0610 & 0412 and ISUNEPCA 0616) carried out in different years, biological samples and videos were obtained in Gazul MV (Spanish Margin of the GoC). The study of those samples and videos has revealed the presence of several ecologically important VMEs (e.g. 3 species of reef framework-forming corals, coral gardens including solitary scleractinians, gorgonians and antipatharians, as well as deep-sea sponge aggregations and chemosynthesis-related structures) and a large number of species occurring in this MV, including new records for the European margin, threatened species and non-previously described species. The combination of different environmental and anthropogenic factors allowed the present-day persistence of these VMEs in the GoC. Some of Gazul MV biological and ecological attributes fit several criteria of the Convention on Biological Diversity for EBSA description (e.g. 1,3,4,6) that, together with those of other areas of the GoC, may contribute to the future potential nomination of an EBSA in this area of the NE Atlantic

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.</p

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Background: Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. // Methods: We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung's disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. // Findings: We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung's disease) from 264 hospitals (89 in high-income countries, 166 in middle-income countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in low-income countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. // Interpretation: Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between low-income, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030